Exploitation of host epithelial signaling networks by respiratory bacterial pathogens

Journal Pharmacological Sciences

Volumn 91, Issue 1, 2003, Pages 1-7

  Li, Jian Dong ^a,b  

^a HOUSE EAR INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Glucocorticoids; Nontypeable Haemophilus influenzae; Nuclear factor B; p38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AUTACOID; DEXAMETHASONE; GLUCOCORTICOID; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 2; MUCIN 5AC; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN KINASE B; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; BACTERIUM IDENTIFICATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE MARKER; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIUM CELL; HAEMOPHILUS INFLUENZAE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BACTERIAL INFECTIONS; EPITHELIAL CELLS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; RESPIRATORY TRACT INFECTIONS; SIGNAL TRANSDUCTION;

EID: 0038730882     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.91.1     Document Type: Review

References (47)

1. Foxwell AR, Kyd JM and Cripps AW: Nontypeable Haemophilus influenzae: Pathogenesis and prevention. Microbiol Mol Biol Rev 62, 294-308 (1998)
2. Murphy TF: Bacterial otitis media: Pathogenetic considerations. Pediatr Infect Dis J 19, Suppl 5, S9-S15 (2000)
3. Bluestone CD: Otitis media in children: To treat or not to treat? N Engl J Med 306, 1399-1404 (1982)
4. ATS Statement: Am J Respir Crit Care Med 152, Suppl 5, 78S-121S (1995)
5. Murphy TF: Haemophilus influenzae in chronic bronchitis. Semin Respir Infect 15, 41-51 (2000)
6. Bluestone CD: Clinical course, complications and sequelae of acute otitis media. Pediatr Infect Dis J 19, Suppl 5, S37-S46 (2000)
7. Di Mango E, Ratner AJ, Bryan R, Tabibi S and Prince A: Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 101, 2598-2605 (1998)
8. Melhus A and Ryan AF: Expression of cytokine genes during pneumococcal and nontypeable Haemophilus influenzae acute otitis media in the rat. Infect Immun 68, 4024-4031 (2000)
9. Hatada EN, Krappmann D and Scheidereit C: NF-kappaB and the innate immune response. Curr Opin Immunol 12, 52-58 (2000)
10. Stancovski I and Baltimore D: NF-kappaB activation: The I kappaB kinase revealed? Cell 91, 290-302 (1997)
11. Karin M: How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex. Oncogene 18, 6867-6874 (1999)
12. Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, Murphy T, Lim DJ and Li JD: Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha/beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci USA 98, 8774-8779 (2001)
13. Jono H, Xu H, Kai H, Gum J, Kim YS, Feng XH and Li JD: Direct activation of TGF-β-Smad signaling by nontypeable Haemophilus influenzae mediates host defensive responses. J Biol Chem 277, 45547-45557 (2002)
14. Shuto T, Imasato I, Jono H, Xu H, Watanabe T, Kai H, Andalibi A, Linthicum F, Guan YL, Han J, Cato AC, Akira S, Lim DJ and Li JD: Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem 277, 17263-17270 (2002)
15. Schulze-Osthoff K, Ferrari D, Riehemann K and Wesselborg S: Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology 198, 35-49 (1997)
16. Ono K and Han J: The p38 signal transduction pathway: Activation and function. Cell Signal 12, 1-13 (2000)
17. New L and Han J: The p38 MAP kinase pathway and its biological function. Trends in Cardiovascular Medicine 8, 220-228 (1998)
18. Han J, Jiang Y, Li Z, Kravchenko VV and Ulevitch RJ: MEF2C participates in inflammatory responses via p38 activation. Nature 386, 296-299 (1997)
19. New L, Jiang Y, Zhao M, Liu K, Flood L, Kato Y, Parry GC and Han J: PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J 17, 3371-3384 (1998)
20. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR and Lee JC: SB203580 is a specific inhibitor of a MAPK homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364, 229-233 (1995)
21. Young PR, McLaughlin MM, Kumar S, Adams JL and Lee JC: Pyridinyl imidazole inhibitors of p38 MAP kinase bind in the ATP site. J Biol Chem 272, 12116-12121 (1997)
22. Adams JL and Lee D: Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases. Curr Opin Drug Discov Develop 2, 96-109 (1999)
23. Wang B, Lim DJ, Han J, Kim YS, Basbaum CB and Li JD: Novel cytoplasmic proteins of nontypeable Haemophilus influenzae up-regulate human MUC5AC mucin transcription via a positive p38 mitogen-activated protein kinase pathway and a negative phosphoinositide 3-kinase-Akt pathway. J Biol Chem 277, 949-957 (2002)
24. Duronio V, Scheid MP and Ettinger S: Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal 10, 233-239 (1998)
25. Kane LP, Shapiro VS, Stokoe D and Weiss A: Induction of NF-kappaB by the Akt/PKB kinase. Current Biology 9, 601-604 (1999)
26. Bierne H, Dramsi S, Gratacap MP, Randriamampita C, Carpenter G, Payrastre B and Cossart P: The invasion protein InIB from Listeria monocytogenes activates PLC-gamma1 downstream from PI 3-kinase. Cell Microbiol 2, 465-476 (2000)
27. Madge LA and Pober JS: A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NFkappaB in human endothelial cells. J Biol Chem 275, 15458-15465 (2000)
28. Gratton JP, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K and Sessa WC: Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotein in endothelial cells. J Biol Chem 276, 30359-30365 (2001)
29. Derynck R and Feng XH: TGF-β receptor signaling. Biochim Biophys Acta 1333, F105-F150 (1997)
30. Derynck R, Zhang Y and Feng XH: Smads: Transcriptional activators of TGF-β responses. Cell 95, 737-740 (1998)
31. Piek E, Heldin CH, Ten Dijke P: Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 13, 2105-2124 (1999)
32. Massague J and Wotton D: Transcriptional control by the TGF-β/Smad signaling system. EMBO J 19, 1745-1754 (2000)
33. Massague J: How cells read TGF-β signals. Nat Rev Mol Cell Biol 1, 169-178 (2000)
34. Hill CS: TGF-β signalling pathways in early Xenopus development. Curr Opin Genet Dev 11, 533-540 (2001)
35. Roberts AB: The ever-increasing complexity of TGF-β signaling. Cytokine Growth Factor Rev 13, 3-5 (2002)
36. Zhang Y, Feng XH and Derynck R: Smad 3 and Smad 4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 394, 909-913 (1998)
37. Lopez-Rovira T, Chalaux E, Rosa JL, Bartrons R and Ventura F: Interaction and functional cooperation of NF-κB with Smads. Transcriptional regulation of the junB promoter. J Biol Chem 275, 28937-28946 (2000)
38. Feng XH, Lin X and Derynck R: Smad 2, Smad 3 and Smad 4 cooperate with Sp1 to induce p15 (Ink4B) transcription in response to TGF-β. EMBO J 19, 5178-5193 (2000)
39. Wilckens T and De Rijk R: Glucocorticoids and immune function: Unknown dimensions and new frontiers. Immunol Today 18, 418-424 (1997)
40. Wilckens T: Glucocorticoids and immune function: Physiological relevance and pathogenic potential of hormonal dysfunction. Trends Pharmacol Sci 16, 193-197 (1995)
41. Karin M: New twists in gene regulation by glucocorticoid receptor: Is DNA binding dispensable? Cell 93, 487-490 (1998)
42. Cato AC and Wade E: Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 18, 371-378 (1996)
43. Webster JC and Cidlowski JA: Mechanisms of glucocorticoid-receptor-mediated repression of gene expression. Trends Endocrinol Metab 10, 396-402 (1999)
44. Takeuchi O, Hoshino K and Akira S: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 165, 5392-5396 (2000)
45. Sun H, Charles CH, Lau LF and Tonks NK: MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75, 487-493 (1993)
46. Groom LA, Sneddon AA, Alessi DR, Dowd S and Keyse SM: Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J 15, 3621-3632 (1996)
47. Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S and Li JD: Enhancement of NTHi-induced TLR2 expression by glucocorticoids via MKP-1-dependent inhibition of p38 MAPK. J Biol Chem 277, 47444-47450 (2002)